Foster & Motley’s AbbVie ABBV Stock Holding History

Foster & Motley’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$12.2M	Buy	56,317 +328	+0.6%	+$72.8K	0.63%	32
2025 Q4	$12.8M	Sell	55,989 -1,751	-3%	-$399K	0.68%	32
2025 Q3	$13.4M	Sell	57,740 -571	-1%	-$116K	0.72%	29
2025 Q2	$10.8M	Buy	58,311 +619	+1%	+$115K	0.63%	35
2025 Q1	$12.1M	Sell	57,692 -853	-1%	-$166K	0.76%	26
2024 Q4	$10.4M	Buy	58,545 +900	+2%	+$165K	0.68%	30
2024 Q3	$11.4M	Sell	57,645 -3,159	-5%	-$590K	0.72%	33
2024 Q2	$10.4M	Buy	60,804 +910	+2%	+$151K	0.72%	31
2024 Q1	$10.9M	Buy	59,894 +1,145	+2%	+$197K	0.75%	33
2023 Q4	$9.1M	Buy	58,749 +1,067	+2%	+$156K	0.68%	35
2023 Q3	$8.6M	Buy	57,682 +128	+0.2%	+$18.8K	0.7%	30
2023 Q2	$7.75M	Buy	57,554 +905	+2%	+$133K	0.6%	33
2023 Q1	$9.03M	Buy	56,649 +1,022	+2%	+$156K	0.73%	24
2022 Q4	$8.99M	Sell	55,627 -93	-0.2%	-$14.3K	0.77%	24
2022 Q3	$7.48M	Buy	55,720 +849	+2%	+$122K	0.71%	31
2022 Q2	$8.4M	Buy	54,871 +1,386	+3%	+$212K	0.74%	31
2022 Q1	$8.67M	Buy	53,485 +1,028	+2%	+$149K	0.68%	33
2021 Q4	$7.1M	Buy	52,457 +1,221	+2%	+$144K	0.55%	47
2021 Q3	$5.53M	Sell	51,236 -446	-0.9%	-$51K	0.46%	55
2021 Q2	$5.82M	Buy	51,682 +5,046	+11%	+$568K	0.49%	54
2021 Q1	$5.05M	Sell	46,636 -570	-1%	-$61K	0.42%	62
2020 Q4	$5.06M	Sell	47,206 -642	-1%	-$61.7K	0.49%	55
2020 Q3	$4.19M	Buy	47,848 +15	+0%	+$1.41K	0.49%	56
2020 Q2	$4.7M	Buy	47,833 +1,071	+2%	+$94.3K	0.59%	49
2020 Q1	$3.56M	Buy	46,762 +5,223	+13%	+$445K	0.53%	52
2019 Q4	$3.68M	Sell	41,539 -888	-2%	-$73.7K	0.46%	61
2019 Q3	$3.21M	Sell	42,427 -1,722	-4%	-$118K	0.44%	63
2019 Q2	$3.21M	Sell	44,149 -1,148	-3%	-$90.2K	0.45%	63
2019 Q1	$3.65M	Sell	45,297 -10	-0%	-$818	0.53%	57
2018 Q4	$4.18M	Buy	45,307 +337	+0.7%	+$29.6K	0.67%	42
2018 Q3	$4.25M	Buy	44,970 +909	+2%	+$86.2K	0.64%	49
2018 Q2	$4.08M	Buy	44,061 +3,148	+8%	+$307K	0.65%	45
2018 Q1	$3.87M	Buy	40,913 +2,358	+6%	+$259K	0.63%	49
2017 Q4	$3.73M	Sell	38,555 -536	-1%	-$50.5K	0.6%	53
2017 Q3	$3.47M	Sell	39,091 -135	-0.3%	-$10.3K	0.6%	55
2017 Q2	$2.84M	Sell	39,226 -198	-0.5%	-$13.3K	0.5%	62
2017 Q1	$2.57M	Buy	39,424 +65	+0.2%	+$4.09K	0.47%	70
2016 Q4	$2.46M	Sell	39,359 -50	-0.1%	-$3.05K	0.47%	70
2016 Q3	$2.49M	Sell	39,409 -1,100	-3%	-$71.2K	0.48%	74
2016 Q2	$2.51M	Sell	40,509 -998	-2%	-$60.8K	0.5%	76
2016 Q1	$2.37M	Buy	41,507 +9,365	+29%	+$522K	0.48%	74
2015 Q4	$1.9M	Buy	32,142 +4,345	+16%	+$250K	0.4%	82
2015 Q3	$1.51M	Sell	27,797 -1,603	-5%	-$104K	0.34%	85
2015 Q2	$1.98M	Sell	29,400 -1,948	-6%	-$127K	0.43%	80
2015 Q1	$1.83M	Sell	31,348 -1,678	-5%	-$101K	0.4%	77
2014 Q4	$2.16M	Sell	33,026 -3,555	-10%	-$224K	0.49%	68
2014 Q3	$2.11M	Sell	36,581 -17,365	-32%	-$964K	0.49%	66
2014 Q2	$3.04M	Sell	53,946 -11,600	-18%	-$609K	0.7%	52
2014 Q1	$3.37M	Sell	65,546 -38,109	-37%	-$1.93M	0.83%	47
2013 Q4	$5.47M	Sell	103,655 -24,771	-19%	-$1.22M	1.38%	25
2013 Q3	$5.74M	Sell	128,426 -5,325	-4%	-$236K	1.53%	19
2013 Q2	$5.53M	Buy	+133,751	New	+$5.85M	1.54%	24

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Foster & Motley's ABBV Position: Q1 2026 in Review

Foster & Motley increased its AbbVie (ABBV) stake by 0.59% in Q1 2026, buying an estimated $72.8K and bringing the position to 56,317 shares worth $12.2M. The position accounts for 0.63% of the portfolio, ranked #32.

Foster & Motley first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $13.4M in Q3 2025. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Foster & Motley held 56,317 shares of AbbVie worth $12.2M as of Q1 2026.
Foster & Motley bought 328 AbbVie shares in Q1 2026, an estimated $72.8K.
AbbVie made up 0.63% of Foster & Motley's portfolio in Q1 2026, its #32 holding.
Foster & Motley first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
Foster & Motley's AbbVie position peaked at $13.4M in Q3 2025.
4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Foster & Motley's 13F filing for Q1 2026, filed 21 Apr 2026.